MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease
18.03.2026 - 10:43:49 | prnewswire.co.uk
Merry Life Biomedical Company, Ltd. Taiwan New York